Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 1:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,754 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lipid Metabolism Clear all
Completed Phase 4 Interventional Results available

Vascular Inflammation in Psoriasis - Extension Study

NCT01866592
View directory record Official record
Conditions
Psoriasis, Cardiovascular Disease
Interventions
Adalimumab
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
9
States / cities
Sacramento, California • Denver, Colorado • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 26, 2026, 1:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a Spiced Meat Patty on Inflammation in Men With Type 2 Diabetes

NCT01076829
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
Spice polyphenols
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
35 Years to 70 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Oct 26, 2026, 1:33 PM EDT
Completed Not applicable Interventional

The Effect of Vitamin D Supplementation on Glucose Metabolism in Non-Diabetic African American Adults

NCT01141192
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
vitamin D3, cholecalciferol, Inactive comparator
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
19 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Oct 26, 2026, 1:33 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia

NCT06238466
View directory record Official record
Conditions
Cardiovascular
Interventions
AZD1705, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
5
States / cities
Glendale, California • Jacksonville, Florida • Winter Park, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 26, 2026, 1:33 PM EDT
Completed Phase 2 Interventional Results available

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

NCT05355402
View directory record Official record
Conditions
Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia
Interventions
Olezarsen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
21
States / cities
Lincoln, California • Montclair, California • Boca Raton, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 26, 2026, 1:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effect of Crestor on Lipoprotein Metabolism in Humans

NCT00214617
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Rosuvastatin at 5 mg/day and 40 mg/day
Drug
Lead sponsor
Foundation for Atlanta Veterans Education and Research, Inc.
Other
Eligibility
50 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 26, 2026, 1:33 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus

NCT00760344
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
SYR-472, Placebo, Sitagliptin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
105
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 102 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Oct 26, 2026, 1:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins

NCT01859455
View directory record Official record
Conditions
Hypercholesterolemia, LDL Cholesterol
Interventions
LGT209 50 mg, LGT209 300 mg, Placebo, Statins (atorvastatin or simvastatin)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Fort Myers, Florida • Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 26, 2026, 1:33 PM EDT
Not listed Not applicable Interventional

Diabetes Complication Control in Community Clinics (D4C) Trial

NCT02835287
View directory record Official record
Conditions
Diabetes, Hypertension, Dyslipidemia, Cardiovascular Disease
Interventions
Protocol-based integrated care
Other
Lead sponsor
Tulane University
Other
Eligibility
50 Years and older
Enrollment
11,132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 26, 2026, 1:33 PM EDT
Completed Phase 2 Interventional

Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia

NCT00006493
View directory record Official record
Conditions
HIV Infections, Hyperlipidemia
Interventions
Rosiglitazone
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 1:33 PM EDT
Completed Phase 4 Interventional Results available

Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia

NCT00833976
View directory record Official record
Conditions
High Triglycerides, Hypercholesterolemia, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Lovaza
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 26, 2026, 1:33 PM EDT
Completed Phase 3 Interventional Results available

Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks

NCT03180840
View directory record Official record
Conditions
Fabry Disease
Interventions
Pegunigalsidase alfa
Biological
Lead sponsor
Protalix
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 26, 2026, 1:33 PM EDT
Withdrawn Not applicable Interventional

Low Dose Growth Hormone Treatment in Subjects With Metabolic Syndrome.

NCT00720616
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Norditropin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 26, 2026, 1:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Replacing Energy From Solid Fats and Added Sugars (SoFAS) With Avocado

NCT04990817
View directory record Official record
Conditions
Elevated Triglycerides, Hypertriglyceridemia
Interventions
Average American Diet With SoFAS Replaced With Avocado, Average American Diet
Other
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
21 Years to 74 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
2
States / cities
Chicago, Illinois • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 26, 2026, 1:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

SlimShape Device for Abdominal Fat and Circumference Reduction

NCT02999763
View directory record Official record
Conditions
Fat Disorder
Interventions
SlimShape
Device
Lead sponsor
Syneron Medical
Industry
Eligibility
18 Years to 60 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Sacramento, California • Wayland, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 26, 2026, 1:33 PM EDT
Withdrawn Phase 1 Interventional

A Pilot Study on the Effect of Vitamin D Treatment in Patients With Statin-Associated Myalgia

NCT01274104
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Vitamin D3, Placebo
Dietary Supplement · Other
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years to 88 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 26, 2026, 1:33 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Intermittent Cottonseed Oil Consumption

NCT07246408
View directory record Official record
Conditions
Dyslipidemia, Overweight and Obesity, Nutrition, Healthy
Interventions
CSO-30, CSO-20, Control
Other
Lead sponsor
University of Georgia
Other
Eligibility
25 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 26, 2026, 1:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Access The Safety And Tolerability Of RN316 (PF-04950615) When Administered To Healthy Adult Subjects

NCT00991159
View directory record Official record
Conditions
Healthy
Interventions
RN316
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Phoenix, Arizona • Miami Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Jul 4, 2012 · Synced Oct 26, 2026, 1:33 PM EDT
Recruiting No phase listed Observational

Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions

NCT06676046
View directory record Official record
Conditions
Dyslipidemia, Atherosclerosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 90 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2044
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 26, 2026, 1:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Fish Oil on Plasma Triglycerides in Adults

NCT00804427
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Fish oil (90% triglycerides), Fish oil (60% triglycerides), Fish oil (ethyl esters), Soy oil
Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 26, 2026, 1:33 PM EDT
Terminated Phase 3 Interventional Results available

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

NCT01975376
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
bococizumab (PF-04950615), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
16,784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
545
States / cities
Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 339 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 26, 2026, 1:33 PM EDT
Completed Phase 3 Interventional Results available

Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

NCT02833844
View directory record Official record
Conditions
Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
Interventions
Evolocumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
20
States / cities
Los Angeles, California • Hartford, Connecticut • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 26, 2026, 1:33 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of Quercetin on Metabolic Health

NCT05297032
View directory record Official record
Conditions
Quercetin, Lipid Metabolism, Aging
Interventions
Quercetin Phytosome
Dietary Supplement
Lead sponsor
Thorne HealthTech, Inc
Industry
Eligibility
20 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Summerville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 26, 2026, 1:33 PM EDT
Completed Phase 4 Interventional

A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients

NCT00005764
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Lamivudine/Zidovudine, Abacavir sulfate, Lamivudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
31
States / cities
Los Angeles, California • San Diego, California • Washington D.C., District of Columbia + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 1:33 PM EDT